Hiroshi Yagata1, Hiroshi Ohtsu2, Yoshifumi Komoike3, Shigehira Saji4, Hiroyuki Takei5, Toshitaka Nakamura6, Yasuo Ohashi7, Takuya Iwase8, Kojiro Shimozuma9. 1. Department of Breast Care, Saitama Medical Center, Saitama Medical University, 1981, Kamoda, Kawagoe-shi, Saitama, 350-0844, Japan. yagata@biglobe.jp. 2. Leading Center for the Development and Research of Cancer Medicine, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-Ku, Tokyo, 113-8421, Japan. 3. Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan. 4. Department of Medical Oncology, Fukushima Medical University, 1 Hikariga-oka, Fukushima, 960-1295, Japan. 5. Department of Breast Oncology, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyou-ku, Tokyo, 113-8603, Japan. 6. National Center for Global Health and Medicine Center Hospital, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. 7. Department of Integrated Science and Engineering for Sustainable Society, Chuo University, 1-13-27 Kasuga, Bunkyo-ku, Tokyo, 112-8511, Japan. 8. Department of Breast Surgery, Cancer Institute Hospital, 3-8-31 Ariake, Koto, Tokyo, 135-8550, Japan. 9. Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1, Noji-Higashi, Kusatsu, 525-8577, Japan.
Abstract
PURPOSE: To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer. METHODS:Joint symptoms and HRQOL were evaluated using an original questionnaire for joint symptoms, the Short Form 36-item Health Survey (SF-36), the EuroQol EQ-5D-3L, and a subscale of the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES). RESULTS:Baseline joint symptom and HRQOL data were collected from 330 patients between November 2007 and March 2010. Joint pain and joint stiffness were reported by 61.6 and 59.1 % of patients, respectively, although these symptoms did not affect the activities of daily living in 96.0 and 97.9 % of patients, respectively. Joint pain was reported in the knee by 61.0 % of patients and in the hand by 36.0 % of patients. Joint stiffness mainly affected the hand (67.9 %), especially the proximal interphalangeal joint, and typically occurred upon waking up or in the morning. Most SF-36 domains had good average scores, although slight decreases in physical functioning and role-physical were observed (compared to the national standard scores). The mean EQ-5D utility score was 0.86, and the total FACT-ES subscale score was 62.2/76. CONCLUSIONS: After 5 years of anastrozole, many of the patients reported joint pain and stiffness in mainly the hand and knee with mild symptoms and good HRQOL.
RCT Entities:
PURPOSE: To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer. METHODS: Joint symptoms and HRQOL were evaluated using an original questionnaire for joint symptoms, the Short Form 36-item Health Survey (SF-36), the EuroQol EQ-5D-3L, and a subscale of the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES). RESULTS: Baseline joint symptom and HRQOL data were collected from 330 patients between November 2007 and March 2010. Joint pain and joint stiffness were reported by 61.6 and 59.1 % of patients, respectively, although these symptoms did not affect the activities of daily living in 96.0 and 97.9 % of patients, respectively. Joint pain was reported in the knee by 61.0 % of patients and in the hand by 36.0 % of patients. Joint stiffness mainly affected the hand (67.9 %), especially the proximal interphalangeal joint, and typically occurred upon waking up or in the morning. Most SF-36 domains had good average scores, although slight decreases in physical functioning and role-physical were observed (compared to the national standard scores). The mean EQ-5D utility score was 0.86, and the total FACT-ES subscale score was 62.2/76. CONCLUSIONS: After 5 years of anastrozole, many of the patients reported joint pain and stiffness in mainly the hand and knee with mild symptoms and good HRQOL.
Entities:
Keywords:
Anastrozole; Breast cancer; Joint pain and stiffness; Quality of life
Authors: A Buzdar; A Howell; J Cuzick; C Wale; W Distler; G Hoctin-Boes; J Houghton; G Y Locker; J M Nabholtz Journal: Lancet Oncol Date: 2006-08 Impact factor: 41.316
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Hyman B Muss; Dongsheng Tu; James N Ingle; Silvana Martino; Nicholas J Robert; Joseph L Pater; Timothy J Whelan; Michael J Palmer; Martine J Piccart; Lois E Shepherd; Kathleen I Pritchard; Zhi He; Paul E Goss Journal: J Clin Oncol Date: 2008-03-10 Impact factor: 44.544
Authors: John F Forbes; Jack Cuzick; Aman Buzdar; Anthony Howell; Jeffrey S Tobias; Michael Baum Journal: Lancet Oncol Date: 2008-01 Impact factor: 41.316
Authors: Kannie Chim; Sharon X Xie; Carrie T Stricker; Qing S Li; Robert Gross; John T Farrar; Angela DeMichele; Jun J Mao Journal: BMC Cancer Date: 2013-09-03 Impact factor: 4.430
Authors: Tao Wang; Yu-Yan Huang; Xian-Liang Liu; Alex Molassiotis; Li-Qun Yao; Si-Lin Zheng; Jing-Yu Benjamin Tan; Hou-Qiang Huang Journal: Support Care Cancer Date: 2022-09-06 Impact factor: 3.359
Authors: Hsu-Chih Chien; Yea-Huei Kao Yang; C Kent Kwoh; Pavani Chalasani; Debbie L Wilson; Wei-Hsuan Lo-Ciganic Journal: J Clin Med Date: 2020-02-19 Impact factor: 4.241
Authors: Manraj N Kaur; Jiajun Yan; Anne F Klassen; Justin P David; Dilshan Pieris; Manraj Sharma; Louise Bordeleau; Feng Xie Journal: Med Decis Making Date: 2022-01-18 Impact factor: 2.749